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Atopic dermatitis (AD) is a chronic itch and inflamma-
tory disorder of the skin that affects one in ten peo-
ple. Patients suffering from severe AD eventually
progress to develop asthma and allergic rhinitis, in
a process known as the ‘‘atopic march.’’ Signaling
between epithelial cells and innate immune cells via
the cytokine thymic stromal lymphopoietin (TSLP)
is thought to drive AD and the atopic march. Here,
we report that epithelial cells directly communicate
to cutaneous sensory neurons via TSLP to promote
itch. We identify the ORAI1/NFAT calcium signaling
pathway as an essential regulator of TSLP release
from keratinocytes, the primary epithelial cells of
the skin. TSLP then acts directly on a subset of
TRPA1-positive sensory neurons to trigger robust
itch behaviors. Our results support a model whereby
calcium-dependent TSLP release by keratinocytes
activates both primary afferent neurons and immune
cells to promote inflammatory responses in the skin
and airways.
INTRODUCTION
Atopic dermatitis (AD) is a chronic itch and inflammatory disorder
of the skin that affects one in ten people. AD is primarily charac-
terized by intolerable and incurable itch. Up to 70% of AD
patients go on to develop asthma in a process known as the
‘‘atopic march’’ (He and Geha, 2010; Locksley, 2010; Spergel
and Paller, 2003; Ziegler et al., 2013). Numerous studies suggest
that the cytokine thymic stromal lymphopoietin (TSLP) acts as a
master switch that triggers both the initiation andmaintenance of
AD and the atopic march (Moniaga et al., 2013; Ziegler et al.,
2013). TSLP is highly expressed in human cutaneous epithelial
cells in AD and bronchial epithelial cells in asthma (Jariwala
et al., 2011). Overexpression of TSLP in keratinocytes, the
most prevalent cell type in the skin, triggers robust itch-evokedscratching, the development of an AD-like skin phenotype, and
ultimately asthma-like lung inflammation in mice (Li et al.,
2005; Ying et al., 2005; Ziegler et al., 2013). However, the mech-
anisms by which TSLP triggers itch and AD remain enigmatic.
Itch is mediated by primary afferent somatosensory neurons
that havecell bodies in thedorsal rootganglia (DRG) that innervate
the skin andareactivatedbyendogenouspruritogens todrive itch
behaviors (Ikoma et al., 2006; McCoy et al., 2012; Ross, 2011).
Hallmarks of AD skin include robust itch sensations, increased
neuronal activity, and hyperinnervation (Ikoma et al., 2003; Tobin
et al., 1992; Tominaga et al., 2009). Although many studies have
shown that epithelial cell-derived TSLPactivates T cells, dendritic
cells, andmast cells (Ziegler et al., 2013), the role of sensory neu-
rons in this pathway hasnot been studied.HowdoesTSLP lead to
sensory neuron activation to promote itch?
In vitro studies suggest that keratinocytes may directly
communicate with sensory neurons via neuromodulators (Ikoma
et al., 2006). Indeed, many of the factors that keratinocytes
secrete act on both immune cells and primary afferent sensory
neurons (Andoh et al., 2001; Fitzsimons et al., 2001; Kanda
et al., 2005; Ziegler et al., 2013). Thus, TSLP may evoke itch
behaviors directly, by activating sensory neurons, indirectly, by
activating immune cells that secrete inflammatory mediators
that target sensory neurons, or both. Although TSLP’s action
on immune cells is well characterized, its effects on sensory neu-
rons, and the contribution of sensory neurons to TSLP-evoked
atopic disease, have not been studied. Furthermore, the mech-
anisms regulating TSLP release by keratinocytes are unknown.
The GPCR protease-activated receptor 2 (PAR2) plays a key
role in keratinocyte TSLP production. Studies have shown a cor-
relation between PAR2 activity and TSLP expression in the skin
of AD patients and in mouse models of atopic disease (Briot
et al., 2009, 2010; Hovnanian, 2013). In addition, PAR2 activation
triggers robust TSLP expression in keratinocytes (Kouzaki et al.,
2009;Moniaga et al., 2013). Although there is a strong correlation
between PAR2 activity and TSLP levels in the skin, virtually
nothing is known about the molecular mechanisms by which
PAR2 leads to TSLP expression.
Here, we sought to elucidate the mechanisms that regulate
TSLP secretion and that promote TSLP-evoked itch. OurCell 155, 285–295, October 10, 2013 ª2013 Elsevier Inc. 285
Figure 1. TSLP Triggers Robust Itch Behav-
iors in Mice by Activating Sensory Neurons
(A) PCR analysis of TSLPR and IL7Ra in mouse
(left) and human (right) dorsal root ganglia (DRG).
No product was amplified from the ‘‘no RT’’
control.
(B) Image of itch-evoked scratching following
intradermal injection of TSLP (2.5 mg/20 ml) into
the cheek.
(C) Quantification of scratching following TSLP
injection in the cheek. TSLP (black) induced robust
scratching compared to vehicle (white). nR 18 per
group.
(D) Itch behavior in RAG+/+, RAG/, NOD, and
NOD/SCID mice following vehicle (PBS) or TSLP
cheek injection. nR 8 per group.
(E) Itch behavior in cKIT+/+ and cKIT/ mice
following vehicle (PBS) or TSLP injection. nR 8 per
group.
(F) TSLP-evoked scratching following neuronal
ablation by RTX (red) versus control (black). nR 6
per group. *p < 0.05; **p < 0.01; ***p < 0.001. Error
bars represent SEM.findings show that keratinocyte-derived TSLP activates sensory
neurons directly to evoke itch behaviors. We define a subset of
sensory neurons that require both functional TSLP receptors
and the ion channel, TRPA1, to promote TSLP-evoked itch
behaviors, and we identify the ORAI1/NFAT signaling pathway
as a key regulator of PAR2-mediated TSLP secretion by epithe-
lial cells.
RESULTS
TSLP Evokes Robust Itch Behaviors in Mice
To identify proteins that mediate itch transduction in somatosen-
sory neurons, we looked for biomarkers of AD (Lee and Yu, 2011)
in the mouse DRG transcriptome (Gerhold et al., 2013). We were
surprised to find expression of the TSLP receptor (TSLPR) in
mouse sensory ganglia. Although studies have shown that
TSLP acts on various immune cells, TSLP signaling in the ner-
vous system has not been reported. TSLPR is a heterodimer,
composed of the IL7 receptor alpha (IL7Ra) chain and a TSLP-
specific receptor chain (TSLPR; also Crlf2) (Pandey et al.,
2000). Consistent with the presence of TSLPRs in sensory neu-286 Cell 155, 285–295, October 10, 2013 ª2013 Elsevier Inc.rons, we detected both TSLPR and
IL7Ra transcripts in mouse and human
DRG using RT-PCR (Figure 1A).
Somatosensory neurons mediate itch,
touch, and pain. Thus, we asked if TSLP
injection triggers itch and/or pain behav-
iors by using a mouse cheek model of
itch, which permits easy distinction
between these behaviors (Shimada and
LaMotte, 2008). Injection of TSLP into
the cheek of wild-type mice evoked
robust scratching that was not observed
following vehicle injection (Figures 1B
and 1C). Wiping was never observed,indicating that TSLP triggers itch, rather than pain (Shimada
and LaMotte, 2008). Intradermal injection of TSLP has been pre-
viously shown to evoke inflammation of the skin and lung over
the course of hours or days (Jessup et al., 2008). However, we
observed robust itch behaviors within 5 min of TSLP injection
(latency to scratch = 4.1 ± 0.3 min).
Although immune cells play a key role in long-term TSLP-
evoked inflammation, whether immune cells are required for
acute TSLP-triggered itch behaviors is unknown. The current
model posits that TSLP acts on various immune cells to promote
TH2 cell differentiation and inflammation. We thus compared
TSLP-evoked itch behaviors of wild-type mice to mouse strains
lacking either T and B cells (RAG1/, NOD SCID) or mast cells
(Kit(W-sh) (Figures 1D and 1E). TSLP triggered robust itch be-
haviors in all strains, with no significant differences between
transgenic and congenic wild-type littermates. Together, these
data indicate that acute TSLP-evoked itch does not specifically
require lymphocytes or mast cells, nor does it require the
cytokines or other products produced when these cells are
activated, and suggest that TSLP may act directly on sensory
neurons.
Figure 2. TSLP Receptor Components Are
Expressed in Sensory Neurons
(A) DIC overlay images of in situ hybridization with
cDNA probes detecting TSLPR, IL7Ra, and TRPV1
in mouse DRG. Scale bar, 400 mm.
(B) Immunostaining of DRG sections with anti-
bodies against peripherin and TSLPR in DRG
sections. White arrows (right) mark peripherin- and
TSLPR-positive neurons. Scale bar, 400 mm. nR 4
mice/condition.
(C) Immunostaining of PGP 9.5 and TSLPR in
glabrous hind paw skin. The white arrows (right)
mark PGP 9.5- and TSLPR-positive neurons. Scale
bar, 200 mm. nR 3 mice per condition.Previous studies have shown that intradermal injection of
the TRPV1 agonist, resiniferatoxin (RTX), results in ablation
of primary afferent sensory neurons that express TRPV1, or
TRPV1 and TRPA1 and consequently eliminates pain and itch
behaviors (Imamachi et al., 2009; Mitchell et al., 2010). TSLP-
evoked scratching was significantly decreased in RTX-treated
mice as compared to control mice (Figure 1F). These findings
show that the AD cytokine, TSLP, induces itch via sensory
neurons.
TSLP Directly Activates an Uncharacterized Subset of
Sensory Neurons
We next asked whether TSLPRs are expressed in sensory neu-
rons. DRG neurons are a heterogeneous population of cells,
including a subset of small-diameter, peripherin-positive neu-
rons that transmit itch and pain signals to the CNS, and release
inflammatory mediators in the skin and other target organs (Bas-
baum et al., 2009). We thus examined the prevalence of TSLPR-
positive neurons and colocalization with known neuronal
markers. In situ hybridization revealed that TSLPR and IL7Ra
were expressed in a subset of small diameter DRG neurons (Fig-
ure 2A). Using antibodies against TSLPR, we observed TSLPR
protein expression in 5.9% of cells in DRG sections (Figure 2B).
Costaining of TSLPR and peripherin, a marker of small-diameter
DRGneurons, demonstrated that all TSLPR-positive neurons are
also peripherin-positive, with an average diameter of 18.1 ±
0.6 mm (Figure 2B). Overall, the characteristics of TSLPR-positive
neurons match those of sensory neurons that mediate itch and/
or pain (McCoy et al., 2013).
If TSLPRs mediate somatosensory transduction, they should
localize to primary afferent nerve terminals in the skin. We
thus performed immunohistochemistry with antibodies againstCell 155, 285–295TSLPR and the pan-neuronal fiber marker
PGP9.5 on mouse skin (Figure 2C). We
observed TSLPR staining in 9% of
PGP9.5-positive free nerve endings in
the skin (Figure 2C). These data show
that TSLPRs are localized to sensory
neuronal endings that innervate the skin
in close apposition to keratinocytes in
the epidermis. Taken together, these
data demonstrate that the TSLPR sub-
units are expressed in a subset of sen-sory neurons that innervate the skin and mediate itch and/or
pain transduction.
To test whether TSLPR is functional in sensory neurons, we
used ratiometric Ca2+ imaging (Figures 3A and 3B). We found
that 4.1% ± 0.6% of DRG neurons showed robust increases in
intracellular Ca2+ following TSLP application (Figure 3E); this is
similar to the percentage of neurons that respond to other
endogenous pruritogens, like BAM8-22 (Liu et al., 2009; Wilson
et al., 2011). Previous studies have shown that small diameter
sensory neurons transduce itch and/or pain signals via the ion
channels TRPA1 and TRPV1 (Basbaum et al., 2009; Ross,
2011). Indeed, subsequent exposure to the TRPA1 agonist, allyl
isothiocyanate (AITC), or the TRPV1 agonist, capsaicin (CAP),
further increased Ca2+ levels in all TSLP-positive cells (Figures
3A and 3B). Similarly, TSLP triggered action-potential firing in a
subset of CAP-sensitive neurons (Figure 3C). These data sug-
gest that TSLP activates a subset of TRPV1- and TRPA1-positive
sensory neurons. The itch compounds histamine, chloroquine
(CQ), and BAM8-22 have been shown to activate 5%–20% of
sensory neurons (Ikoma et al., 2006; Imamachi et al., 2009; Liu
et al., 2009; Wilson et al., 2011) that express TRPA1 and/or
TRPV1. TSLP appears to activate an undescribed subset of
itch neurons, as most TSLP-positive neurons were insensitive
to other itch compounds (Figures 3A, 3B, and 3D).
TSLPR and TRPA1 Mediate TSLP-Evoked Neuronal
Activation
To ask whether TSLPRs mediate TSLP-evoked neuronal activa-
tion, we examined TSLP-evokedCa2+ signals in neurons isolated
from IL7Ra-deficient mice. TSLP-, but not AITC- or CAP-evoked
Ca2+ signaling, was abolished in IL7a-deficient neurons (Fig-
ure 3E). These results are consistent with previous studies in, October 10, 2013 ª2013 Elsevier Inc. 287
Figure 3. TSLP Directly Activates a Subset
of Sensory Neurons
(A) Representative images of Fura-2 loaded DRG
neurons treated with vehicle, TSLP (2 ng/ml), his-
tamine (HIS, 1 mM), AITC (200 mM), and capsaicin
(CAP, 1 mM).
(B) Representative trace shows a neuron that
responds to TSLP, AITC, and CAP, but not HIS.
(C) Current-clamp recording showing TSLP- and
CAP-evoked action potential firing in a DRG
neuron. nR 60 cells.
(D) A small percentage of the TSLP-sensitive
population overlaps with the population of hista-
mine- (HIS, 6%) or chloroquine-sensitive neurons
(CQ, 6%), but not the BAM8-22 population
(BAM, 0%).
(E) Left: prevalence of TSLP sensitivity in wild-type
neurons (black), IL7Ra-deficient (gray) neurons,
neurons treated with 20 mM ruthenium red (RR;
red), TRPA1-deficient neurons (blue) and TRPV1-
deficient neurons (white). Right: prevalence of
AITC and CAP sensitivity in wild-type (black) and
IL7Ra-deficient (gray) neurons nR 1000 cells.
(F) Prevalence of TSLP sensitivity in neurons pre-
treated with vehicle (black), a PLC blocker,
U73122 (red), and the Gbg blocker, gallein (gray)
nR 600 cells.
(G) Representative response to TSLP in the
absence (0mMCa2+) and presence (2 mMCa2+) of
extracellular Ca2+ n R 200 cells. *p < 0.05; **p <
0.01; ***p < 0.001. Error bars represent SEM.immune cells showing that functional IL7Ra is required for TSLP
signaling (Pandey et al., 2000). Here, we show that functional
TSLPRs are required for TSLP-evoked neuronal activation.
TRPV1 and TRPA1 channels are required for acute itch
signaling and behavior (Ross, 2011). We thus asked whether
these channels are required for TSLP-evoked neuronal activa-
tion. TRPV1 and TRPA1 inhibition by the nonselective inhibitor,
ruthenium red, significantly decreased neuronal sensitivity to
TSLP (Figure 3E). We also compared neurons isolated from
TRPA1- and TRPV1-deficient mice to those from wild-type litter-
mates. TSLP-evoked Ca2+ signals were significantly attenuated
in TRPA1-deficient neurons, but not TRPV1-deficient neurons
(Figure 3E). Our results show that TRPA1 channels mediate
TSLP-evoked neuronal excitability.
We next examined the mechanisms by which TSLPR activa-
tion promotes TRPA1 activity. Two signaling pathways have
linked itch receptors to TRPA1 activation: phospholipase C
(PLC) signaling couples MrgprC11 to TRPA1; and, Gbg signaling288 Cell 155, 285–295, October 10, 2013 ª2013 Elsevier Inc.couples MrgprA3 to TRPA1 (Wilson et al.,
2011). Treatment of cells with the PLC
inhibitor, U73122, significantly reduced
the prevalence of TSLP-sensitive neurons
(Figure 3F). In contrast, gallein, a Gbg
inhibitor, had no effect on TSLP-evoked
Ca2+ signals (Figure 3F). Consistent
with TSLP activation of the PLC path-
way, TSLP triggers both release of Ca2+
from intracellular stores and subsequentCa2+ influx in sensory neurons (Figure 3G). Overall, these exper-
iments suggest that TSLPR and TRPA1 communicate via PLC
signaling.
TSLPR and TRPA1 Mediate TSLP-Evoked Itch
To test whether TSLP and TRPA1 receptors are required for
TSLP-evoked itch behaviors, we used the cheek model of itch.
TSLP-evoked scratching was significantly attenuated in IL7Ra-
deficient mice, supporting a role for TSLPRs in TSLP itch
signaling (Figure 4A). These mice were not generally deficient
in itch behaviors, as CQ-evoked scratching, which occurs via
MrgprA3 (Liu et al., 2009), was normal (Figure 4B). These data
demonstrate that TSLP targets TSLPRs to trigger itch behaviors
in vivo.
We next asked whether TSLP-evoked itch behaviors require
TRP channels. TSLP-evoked scratching was abolished in
TRPA1-deficient mice, but normal in TRPV1-deficient mice (Fig-
ure 4D). These experiments show that both functional TSLPRs
Figure 4. TSLP Induces Robust TSLPR- and
TRPA1-Dependent Itch Behaviors
(A) Itch behaviors following intradermal cheek
injection of vehicle (10 ml PBS, white) or TSLP
(2.5 mg/10 ml) into wild-type (WT; black) or
IL7Ra-deficient (red) mice.
(B) Scratching in WT (black) and IL7Ra-deficient
(red) mice following chloroquine (CQ) injection in
the cheek.
(C) Scratching in WT (black), TRPA1-deficient
(red), and TRPV1-deficient (white) mice following
TSLP injection (2.5 mg/10 ml).
(D) Attenuation of TSLP-evoked scratching by
30 min preinjection with the PLC blocker, U73122
(U7) compared to vehicle (VEH).
(E) CQ-evoked scratching in mice preinjected with
U73122 or vehicle. The time spent scratching was
quantified for 20 min after injection. n R 7 mice/
condition. **p < 0.01; ***p < 0.001. Error bars
represent SEM.and TRPA1 channels are required for TSLP-evoked itch. PLC
signaling is also required for the functional coupling between
TSLPR and TRPA1 in vivo, as TSLP-evoked scratching was
significantly attenuated by intradermal injection of U73122.
Such treatment selectively silenced TSLP-evoked behaviors,
as these mice displayed normal CQ-evoked scratching, which
is PLC-independent (Wilson et al., 2011). Overall, these data
demonstrate a role for TSLP as a pruritogen and a robust
activator of sensory neurons and suggest that these neurons
may contribute to the initiation of TSLP-evoked inflammatory
responses in the skin in AD and airways in asthma.
Keratinocyte Release of TSLP Is Ca2+ Dependent
Our data establish a cellular target for TSLP, supporting a
model whereby both immune cells and sensory neurons are
activated by keratinocyte-derived TSLP to drive itch and AD.
What are the upstream mechanisms that govern the expression
and release of TSLP by keratinocytes? Protease signaling via
PAR2 plays a key role in TSLP production and AD. PAR2 activ-
ity, and levels of the endogenous PAR2 agonist, tryptase, are
increased in the skin of AD patients (Steinhoff et al., 2003).
Consistent with a previous study (Ui et al., 2006), injection of
tryptase induced robust itch behaviors in mice (Figure 5A).
Tryptase-evoked itch was significantly attenuated in both
PAR2- and IL7Ra-deficient mice (Figure 5A), consistent with a
pathway where PAR2 signaling promotes the release of TSLP
from keratinocytes, which then acts on TSLPR-positive neurons
to drive itch behaviors. We next sought to determine the
signaling pathways that control PAR2-induced TSLP expres-
sion in keratinocytes.Cell 155, 285–295,Studies on keratinocytes have shown
that the endogenous PAR2 agonist,
tryptase, and the widely used PAR2
ligand mimetic, Ser-Leu-Ile-Gly-Arg-Leu
(SLIGRL), elicits Ca2+ influx (Schechter
et al., 1998; Zhu et al., 2009) and triggers
the Ca2+-dependent release of inflamma-tory mediators (Halfter et al., 2005; Santulli et al., 1995;
Schechter et al., 1998). For example, SLIGRL triggers a rise in
intracellular Ca2+ in keratinocytes (Zhu et al., 2009) and also pro-
motes TSLP expression (Moniaga et al., 2013). We thus asked
if PAR2-evoked TSLP expression is Ca2+-dependent. ELISA
measurements revealed that treatment of keratinocytes with
tryptase or SLIGRL, but not vehicle, triggered the robust secre-
tion of TSLP (Figure 5B). These data show that PAR2 stimulation
of keratinocytes triggers TSLP release.
TSLP secretion was highly dependent on Ca2+. First, TSLP
secretion was not observed in keratinocytes treated with tryp-
tase or SLIGRL in the absence of external Ca2+ (Figure 5B). In
addition, treatment with the drug thapsigargin (TG), which pro-
motes depletion of intracellular Ca2+ stores and subsequent
Ca2+ influx, caused a significant increase in TSLP secretion
(Figure 5B). These data demonstrate that Ca2+ is required and
sufficient to drive TSLP secretion.
A recent study has shown that some PAR2 agonists,
including SLIGRL, also activate the sensory neuron-specific
itch receptor, MrgprC11 (MrgprX1 in human) (Liu et al., 2011).
However, this result does not impact our in vitro studies for
several reasons. First, keratinocytes do not express MrgprX1
(Figure S1A available online). Second, keratinocytes are
insensitive to the MrgprX1-specific ligand, BAM8-22 (Fig-
ure S1B). Third, tryptase-evoked itch is dependent on PAR2
(Figure 5A). Finally, tryptase does not activate MrgprC11 in
mice (Figures S1C–S1D). Overall, our findings support a model
where tryptase- and SLIGRL treatment of keratinocytes pro-
motes PAR2-evoked Ca2+ signaling and subsequent secretion
of TSLP.October 10, 2013 ª2013 Elsevier Inc. 289
Figure 5. PAR2 Activation Promotes Itch Behaviors and
Ca2+-Dependent Release of TSLP
(A) Itch-evoked scratching following injection of tryptase into the cheek (100
pg/20 ml) of wild-type (WT; black), PAR2-deficient (blue) or IL7Ra-deficient
mice (red), or PBS (white, 20 ml) injection into WT mice, nR 8 mice per con-
dition. The time spent scratching was quantified for 1 hr after injection.
(B) TSLP secretion evoked by 24 hr treatment with vehicle (VEH), tryptase
(TRY, 100 nM), tryptase in the absence of extracellular Ca2+ (TRY 0 Ca),
SLIGRL (100 mM), SLIGRL in the absence of extracellular Ca2+ (SLIGRL 0 Ca),
or TG (1 mM). nR 4 replicates/condition *p < 0.05; **p < 0.01; ***p < 0.001. Error
bars represent SEM.ORAI1 and STIM1 Are Required for PAR2-Evoked Ca2+
Influx
We next used ratiometric Ca2+ imaging to dissect the mecha-
nisms underlying PAR2-evoked Ca2+ signals. Consistent with
previous studies, tryptase and SLIGRL evoked a rise in intracel-
lular Ca2+ in keratinocytes (Figures 6A–6C) (Zhu et al., 2009). In
some cells, PAR2 signals via PLC (Dai et al., 2007), and PLC acti-
vation leads to Ca2+-release from IP3-dependent stores and
influx via the store-operated Ca2+ entry (SOCE) pathway. Indeed,
PAR2 activation in keratinocytes induced both Ca2+ release from
intracellular stores and Ca2+ influx, consistent with activation of
SOCE (Figures 6A and 6B).
What are the molecules mediating PAR2-evoked SOCE in
keratinocytes? Both ORAI and TRPC channels have been impli-
cated in SOCE (Cahalan, 2009; Ramsey et al., 2006). We next
asked whether PAR2 activates SOCE via ORAI or TRPC chan-
nels, which can be distinguished by their distinct pharmacolog-
ical profiles (DeHaven et al., 2008; Lis et al., 2007; Zhang et al.,
2008). The drugs 2-aminoethoxydiphenyl borate (2-APB) and
lanthanum (La3+) inhibit ORAI1 and ORAI2 channels, but not
ORAI3 or TRPC channels (DeHaven et al., 2008; Lis et al.,
2007; Zhang et al., 2008). Tryptase and SLIGRL-evoked Ca2+
influx was significantly attenuated by treatment with 2-APB or
La3+. These data show that tryptase and SLIGRL activate the
same SOCE pathway and support a role for ORAI channels in
PAR2-evoked SOCE (Figure 6C).290 Cell 155, 285–295, October 10, 2013 ª2013 Elsevier Inc.ORAI and TRPC channels can also be distinguished by their
distinct biophysical characteristics: ORAI1 and ORAI2 are
Ca2+-selective channels that are inwardly-rectifying, whereas
TRPC channels are outwardly-rectifying, nonselective channels
(Cahalan, 2009; Owsianik et al., 2006; Yeromin et al., 2006).
Thus, we measured SLIGRL-evoked currents using perforated-
patch, voltage-clamp recordings on keratinocytes. Treatment
with SLIGRL triggered an ORAI1/2-like current; the currents
were dependent on extracellular Ca2+, displayed an inwardly-
rectifying current-voltage relationship, and displayed no
measurable reversal potentials below +80mV (Figure 6D). These
results implicate ORAI1 and/or ORAI2 in PAR2-evoked SOCE.
Quantitative PCR demonstrated that keratinocytes express
ORAI1, ORAI2, and the ORAI regulator, stromal interactionmole-
cule 1 (STIM1). We thus examined the role of ORAI1, ORAI2, and
STIM1 in SOCE using siRNA-mediated knockdown. Depletion of
ORAI1 transcripts by 71% or STIM1 transcripts by 84% signifi-
cantly diminished Ca2+ entry in response to SLIGRL as
compared to scrambled control siRNA (Figures 6E–6G). ORAI1
and STIM1 knockdown also significantly attenuated tryptase-
evoked Ca2+ signals (data not shown). In contrast, depletion of
ORAI2 transcripts by 86% had no effect on SLIGRL-evoked
SOCE (Figures 6E and 6G). These data demonstrate that
ORAI1 and STIM1 are required for PAR2-evoked SOCE in human
keratinocytes. ORAI1 and STIM1 knockdown also attenuated
TG-evoked SOCE (Figure 6G), suggesting that ORAI1 is the
primary store-operated Ca2+ pathway in keratinocytes.
PAR2-Activation Induces Ca2+-Dependent NFAT
Translocation and TSLP Secretion
In immune cells, ORAI1 signaling activates NFAT, which triggers
cytokine expression and secretion (Feske et al., 2006; Gwack
et al., 2007). The ORAI1/NFAT pathway may play a similar role
in keratinocytes, promoting the expression and secretion of
TSLP. Consistent with a regulatory role for NFAT in TSLP expres-
sion, two NFAT binding motifs (GGAAAATN) (Rao et al., 1997;
Zhu et al., 2009) are present in the 50-upstream regulatory region
of the human TSLP gene. These findings imply that PAR2 may
trigger NFAT-dependent expression and release of TSLP; how-
ever, the evidence is merely correlative. To directly test this
hypothesis, we measured PAR2-dependent NFAT translocation
and TSLP expression and release in keratinocytes.
Following a rise in Ca2+, NFAT is dephosphorylated by the
Ca2+-dependent phosphatase calcineurin and translocates
from the cytosol to the nucleus to promote transcription of target
genes (Rao et al., 1997). Immunostaining demonstrated that
treatment of keratinocytes with SLIGRL for 30 min induced
robust NFAT translocation to the nucleus (Figures 7A). This
translocation was attenuated by blocking ORAI channels with
2-APB, or by inhibiting NFAT activity with cyclosporine A (CsA),
an inhibitor of calcineurin (Figure 7A); similar results were
observed using live cell imaging of a human keratinocyte cell
line, HaCat, that expressed NFAT-GFP (Figure 7B). These results
show that PAR2 activation induces Ca2+-dependent NFAT
translocation, which may lead to NFAT-dependent changes in
gene expression. In support of this model, PAR2-evoked
SOCE robustly increased expression of TSLP transcripts in
keratinocytes (Figure 7C).
Figure 6. ORAI1 and STIM1Are Required for
PAR2- and TG-Evoked Ca2+ Influx
(A) Representative response to SLIGRL (100 mM)
following pretreatment with vehicle (black) or 2-
aminoethoxydiphenyl borate (50 mM 2-APB; red).
(B) Representative response to tryptase (100 nM)
following pretreatment with vehicle (black) or
2-APB (red).
(C) Average steady state Ca2+ level following
SLIGRL- or tryptase (TRY)-evoked Ca2+ influx
(2 mM Ca2+), in the presence of 2-APB (red),
lanthanum (50 nM La3+, blue), or vehicle (CTRL,
black). nR 1000 cells.
(D) Representative current-voltage trace in the
presence of SLIGRL (100 mM) in perforated-patch,
whole-cell voltage-clamp recordings. Represen-
tative baseline subtracted currents before (red)
and during application of SLIGRL (black). n R 3
cells/condition.
(E) siRNA-induced silencing of STIM1 (red), ORAI1
(blue), and ORAI2 (gray) mRNA in keratinocytes.
Expression was normalized to scrambled-siRNA
control (black). nR 1000 cells.
(F) Representative traces of SLIGRL-evoked
(100 mM) Ca2+ signals following treatment with
siRNA targeting STIM1 (red) or scrambled control
(CTRL, black).
(G) Average steady state Ca2+ concentration after
treatment with SLIGRL (100 mM) or TG (1 mM) in
cells treated with scrambled siRNA (black), STIM1
(red), ORAI1 (blue), or ORAI2 (gray) siRNA. nR 500
cells. *p < 0.05; **p < 0.01, ***p < 0.001. Error bars
represent SEM.
See also Figure S1.We next addressed whether ORAI1/NFAT signaling mediates
PAR2-evoked TSLP release. We found that siRNA-mediated
knockdown of ORAI1 or STIM1 significantly attenuated
SLIGRL-evoked TSLP release by keratinocytes, suggesting
that ORAI1 is required for PAR2-evoked TSLP secretion (Fig-
ure 7D). Likewise, inhibition of NFAT-mediated transcription
with CsA also attenuated TSLP release (Figure 7E), but had no
effect on SOCE-evoked Ca2+ signals (data not shown). In addi-
tion to cutaneous epithelial cells, airway epithelial cells of
patients with allergic rhinitis, AD and asthma also display high
TSLP expression (Ziegler et al., 2013). Previous studies have
shown that TG induces ORAI1-dependent Ca2+ signals in human
airway epithelial cells (Gusarova et al., 2011). Interestingly, we
found that, like keratinocytes, SOCE triggers robust TSLP
expression in human airway epithelial cells, which can be
blocked by CsA (data not shown). These data identify ORAI1-
dependent NFAT activation as a regulator of TSLP expression
and release in both cutaneous and airway epithelial cells.
We next tested the hypothesis that NFAT promotes TSLP
expression in vivo. Mice were treated with SLIGRL, SLIGRLCell 155, 285–295,and CSA, or vehicle via intradermal injec-
tion into the back. TSLP protein levels in
treated skin were measured 3 hr after
injection. Coinjection of CsA significantly
attenuated SLIGRL-evoked TSLP proteinexpression in skin (Figure 7F). Similar results were also observed
with the endogenous PAR2 agonist, tryptase (Figure 7G),
demonstrating that PAR2 triggers TSLP expression via the
Ca2+-calmodulin/NFAT pathway in vivo.
DISCUSSION
TSLP plays a key role in the triad of atopic diseases: asthma,
allergic rhinitis, and atopic dermatitis (Ziegler et al., 2013). Recent
studies have also implicated TSLP in a number of disorders,
including cancer, gastrointestinal diseases, and autoimmunity
(Ziegler et al., 2013). As such, there is much interest in under-
standing the mechanisms of TSLP expression and downstream
effects of TSLP secretion. Here, we present molecular, cellular,
and behavioral data showing that ORAI1/NFAT signaling regu-
lates TSLP release by keratinocytes and that TRPA1 is required
for TSLP-evoked activation of sensory neurons and subsequent
itch behaviors. Our data support amodelwhereby TSLP released
from keratinocytes acts directly on sensory neurons to trigger
robust itch-evoked scratching (Figure 7H).October 10, 2013 ª2013 Elsevier Inc. 291
Figure 7. PAR2 Activation Promotes Ca2+-
Dependent NFAT Translocation and TSLP
Secretion
(A) Representative images displaying cytosolic
and nuclear localization of NFAT (green) and DAPI
(red) in keratinocytes after a 30min incubation with
vehicle (VEH), SLIGRL (100 mM), SLIGRL + 2APB
(50 mM), or SLIGRL + CsA (1 mM). Pretreatment
with 2APB or CsA prevented SLIGRL-induced
NFAT nuclear translocation. nR 300 cells.
(B) Fraction of HaCaT keratinocytes displaying
nuclear localization of NFAT-GFP following treat-
ment with SLIGRL (100 mM; black), SLIGRL and
2APB (50 mM; red), SLIGRL + CsA (1 mM; blue), or
vehicle (VEH; white). nR 1,000 cells.
(C) TSLP expression in human keratinocytes
following a 3 hr treatment with vehicle (VEH, black)
or SLIGRL (100 mM, red). nR 3.
(D) SLIGRL-evoked TSLP release in cells treated
with scrambled (black), STIM1 (red), or ORAI1
siRNA (blue). Secretion was normalized to vehicle-
treated cells (white). nR 3.
(E) TSLP release in response to treatment with
vehicle (VEH, black), SLIGRL (100 mM, red), or
SLIGRL + CsA (1 mM, blue).
(F) Western blot of skin lysates frommice following
intradermal injection with vehicle (VEH), SLIGRL,
or SLIGRL + CsA. Samples were probed with
antibodies against TSLP and calnexin (loading
control). nR 3 mice.
(G) Western blot of skin lysates isolated from mice
following intradermal injection with vehicle (VEH),
tryptase (TRY; 100 pg/20 mL), or tryptase + CsA
(TRY + CsA). Samples were probed with anti-
bodies against TSLP, and actin (loading control). n
R 3 mice. *p < 0.05; **p < 0.01, ***p < 0.001. Error
bars represent SEM.
(H) Schematic diagram depicting the ORAI1
signaling pathway in keratinocytes that links PAR2
to TSLP secretion and activation of itch neurons.
Activation of PAR2 triggers release of Ca2+ from
the ER and activation of STIM1, which opens
ORAI1 channels to promote Ca2+ influx. Ca2+
activates the phosphatase calcineurin, which
dephosphorylates NFAT and causes nuclear
translocation, thus inducing transcription of TSLP.
Secreted TSLP depolarizes a subset of C-fibers to evoke itch, in a TSLPR- and TRPA1-dependent manner. Activation of TRPA1-expressing sensory
neurons can then lead to release of neuropeptides in the skin in a process known as neurogenic inflammation.Sensory Neurons Mediate TSLP-Evoked Itch
Studies on the role of TSLP in promoting atopic disease have
focused solely on its effects on immune cells. A variety of
immune cells are activated by TSLP, including dendritic cells,
T cells, B cells, natural killer cells, mast cells, basophils, and
eosinophils, which together promote allergic inflammation (Zie-
gler et al., 2013). The inflammatory cytokines produced by these
immune cells can activate sensory neurons (Cevikbas et al.,
2007). TSLP expression in keratinocytes leads to robust scratch-
ing in mice, which was previously assumed to occur solely
downstream of immune cell cytokine release (Bogiatzi et al.,
2012; Yoo et al., 2005).
The current model is that sensory neurons are activated down-
stream of TSLP-activated immune cells to induce itch. Our data
support the direct activation of sensory neurons by TSLP. First,292 Cell 155, 285–295, October 10, 2013 ª2013 Elsevier Inc.we show thatmast cell release of histamine, or other pruritogens,
is not required for TSLP-evoked itch behaviors. In addition, his-
tamine-dependent itch requires TRPV1 (Imamachi et al., 2009),
and our data show that TRPV1-deficient mice display normal
TSLP-evoked itch behaviors. Finally, we show that acute
TSLP-evoked itch does not require lymphocytes. These results
were surprising given the well-known role of immune cells in
TSLP-evoked atopic disease. However, until now, studies have
focused on the long-term, rather than the acute effects of
TSLP. These data suggest that the acute versus chronic phases
of TSLP-evoked inflammation may be mediated by distinct
mechanisms. In addition, because activation of primary afferent
neurons triggers the release of inflammatory agents that pro-
mote immune cell chemoattraction and activation (e.g., sub-
stance P) (Basbaum et al., 2009), neuron-to-immune cell
communication may also play a key role in the development of
AD. Thus far, all published studies have focused on global
knockouts of TSLPR. Future studies using tissue-specific TSLPR
knockout mice are required to determine the relative contribu-
tions of sensory neurons and immune cells to both the acute
and chronic phases of AD.
TRPA1 Is Required for TSLP-Evoked Itch
TSLP activates a subset of sensory neurons that express
TSLPRs and the irritant receptor TRPA1. TRPA1-positive sen-
sory neurons are required for the transmission of itch and pain
stimuli to the CNS (Basbaum et al., 2009; Ross, 2011). Recent
studies have shown that TRPA1 is also required for dry skin-
and allergen-evoked chronic itch (Liu et al., 2013; Wilson et al.,
2013), but the endogenous signaling molecules that promote
TRPA1 activation in these itch models are unknown. We now
show that the endogenous AD cytokine, TSLP, leads to TRPA1
activation, downstream of TSLPR. Inhibition of PLC significantly
attenuates such coupling both in vitro and in vivo. Despite the
extensive literature on TSLP in immune cells, little is known about
the signaling pathways activated downstream of TSLPR. The
JAK/STAT pathway has been implicated in TSLP signaling but
thus far, neither TSLPR nor IL7R have been linked to PLC (Ziegler
et al., 2013).
TRPA1 afferents are not restricted to the skin, but also densely
innervate the airways and gastrointestinal tract (Bautista et al.,
2013). Indeed, TRPA1 activation promotes lung inflammation in
mouse models of airway inflammation and asthma and triggers
inflammation in mouse models of inflammatory bowel disease
(Bautista et al., 2013). Interestingly, we found that like keratino-
cytes, Ca2+ signaling through ORAI1 triggers robust TSLP
expression in human airway epithelial cells (data not shown).
Thus, crosstalk between sensory neurons and epithelial cells
via TSLP and TRPA1 may not be restricted to the skin, but
may also occur in the airways and gut. The ‘‘atopic march’’ has
been largely attributed to the actions of epithelial and immune
cells (Holgate, 2007). Future studies using tissue-specific
TSLPR-deficient animals are required to resolve the contribu-
tions of neuronal and immune cell TSLP signaling to atopic dis-
ease. Nonetheless, our findings highlight a potential new role
for TRPA1 and sensory neurons in promoting the atopic march.
ORAI1/NFAT Regulates TSLP Release in Keratinocytes
ORAI1 was first identified as the channel that mediates store-
operated Ca2+ influx required for NFAT-dependent cytokine
expression during immune cell activation; loss of function muta-
tions in ORAI1 and STIM1 lead to severe combined immunode-
ficiencies in patients (Feske, 2010; Feske et al., 2006; Prakriya
et al., 2006; Yeromin et al., 2006). Our work shows that in addi-
tion to lymphocytes, epithelial cells also utilize ORAI1-mediated
Ca2+ influx to regulate cytokine expression and release, suggest-
ing that ORAI1 plays a more general role in the pathogenesis of
inflammatory disease. Thus, ORAI1 may represent a new thera-
peutic target for atopic disease.
A role for the ORAI1/NFAT pathway in AD is consistent with a
number of disparate clinical findings. First, SNPs in the ORAI1
gene have been linked to susceptibility to atopic disease in
humans (Chang et al., 2012) but the role of ORAI1 in AD hadnot been studied. Second, NFAT displays an abnormally high
degree of nuclear localization in the keratinocytes of chronic
itch patients (Al-Daraji et al., 2002), but the consequences of
NFAT activation on AD was unknown. Finally, CsA, an inhibitor
of NFAT-mediated transcription, is a potent immunosuppressant
drug and is often prescribed for itchy inflammatory skin dis-
eases, such as psoriasis and AD (Madan and Griffiths, 2007).
Although its effects have been mainly attributed to immune cell
inhibition, our work suggests that the effectiveness of CsA in
treating chronic itch may, in part, be due to its effects on kerati-
nocyte-mediated TSLP release.
EXPERIMENTAL PROCEDURES
Cell Culture
Primary human epidermal keratinocytes (PromoCell) and HaCaT cells were
cultured in PromoCell Keratinocyte Medium 2 and DMEM, respectively. siRNA
directed against ORAI1, ORAI2, and STIM1 (QIAGEN; 100 ng) were trans-
fected using HiPerFect (QIAGEN). HaCaT cells were transiently transfected
with Lipofectamine 2000 (Invitrogen) using 1 mg HA-NFAT1(1-460)-GFP
plasmid (Addgene 11107). DRG neurons were isolated from P18–30 mice
and cultured as previously described (Wilson et al., 2011). All media and cell
culture supplements were purchased from the UCSF Cell Culture Facility.
Ca2+ Imaging
Ca2+ imaging was carried out as previously described (Wilson et al., 2011).
Physiological Ringer solution: 140 mM NaCl, 5 mM KCl, 10 mM HEPES,
2 mM CaCl2, 2 mM MgCl2, 10 mM D-(+)-glucose, and pH 7.4 with NaOH.
Images were collected and analyzed using MetaFluor (Molecular Devices).
[Ca2+]i was determined from background-corrected F340/F380 ratio images
using the relation [Ca2+]I = K*(R  Rmin)/(Rmax  R) (Almers and Neher,
1985), with the following parameters measured in keratinocytes: Rmin = 0.3;
Rmax = 2.2; and K* = 3 mM. Cells were classified as responders if [Ca
2+]i
increased 15% above baseline.
Electrophysiology
Recordings were collected at 5 kHz and filtered at 2 kHz using an Axopatch
200B and PClamp software. Electrode resistances were 2–6 MU. Perforated
patch internal solution: 140 mM CsCl, 5 mM EGTA, 10 mM HEPES, pH 7.4
with CsOH, and 0.24 mg ml1 Amphotericin B (Rae et al., 1991). Stimulation
protocol: 10ms step to80mV, 150ms ramp from80mV to +80mV. Current
clamp internal solution: 140 mM KCl, 5 mM EGTA, and 10 mM HEPES (pH 7.4
with KOH). Series resistance of all cells were <30MU and liquid junction poten-
tials were <5 mV (no correction).
RT-PCR
RNA was extracted using RNeasy (QIAGEN) and reverse transcription was
performed using Superscript III. RT-PCR was carried out using SYBR Green
(Invitrogen) on a StepOnePlus ABI machine. Threshold cycles for each tran-
script (Bogiatzi et al., 2012) were normalized to GAPDH (DCt). Calibrations
and normalizations used the 2DDCt method where DDCt = [(Ct (target
gene) Ct (reference gene)] [Ct (calibrator)Ct (reference gene)]; GAPDH =
reference gene; scrambled siRNA = calibrator. Experiments were performed
in triplicate.
Histology
Histology was carried out as previously described (Gerhold et al., 2013). Anti-
bodies: rabbit anti-PGP9.5 and rabbit anti-peripherin (Millipore) 1:1,000; goat
anti-TSLPR and mouse anti-NFATc1 (Santa Cruz Biotechnology) 1:100. IL7Ra
and TSLPR probes (Panomics) were used for in situ hybridization following the
Quantigene protocol (Panomics).
Protein Detection
TSLP protein levels were measured using the DuoSet ELISA kit (R&D Systems)
on media collected 24 hr after stimulation. TSLP release was normalized toCell 155, 285–295, October 10, 2013 ª2013 Elsevier Inc. 293
vehicle. For western blots, 50 mg of cleared tissue lysate was resolved by
SDS-PAGE, transferred to nitrocellulose membranes, and probed with anti-
TSLP (1:250, Genetex), anti-Calnexin (1:2,000, Abcam), and anti-Actin
(1:2,000).
Mice and Behavior
Mice (20–35 g) were housed in 12 hr light-dark cycle at 21C. Behavioral mea-
surements were performed as previously described (Wilson et al., 2011). Com-
pounds injected: 2.5 mg TSLP, 200 mgCQ, 100 pg tryptase dissolved in PBS, or
RTX 1 mg/ml in 0.05% ascorbic acid and 7% Tween 80 (2 days prior to pruri-
togen injection). For AITC behavior, 5 ml 10% AITC in mineral oil was applied
to the right hind paw. Behavioral scoring was performed while blind to treat-
ment and genotype. All experiments were performed under the policies and
recommendations of the International Association for the Study of Pain and
approved by the University of California, Berkeley Animal Care and Use
Committee.
Data Analysis
Data are shown as mean ± SEM. Statistical significance was evaluated using a
one-way ANOVA followed by a Tukey-Kramer post hoc test or unpaired two-
tailed Student’s t test for comparing difference between two samples (*p <
0.05, **p < 0.01, ***p < 0.001).
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